Fri, Jun. 24, 7:01 AM
- Cerner (NASDAQ:CERN) upgraded to Buy from Neutral with $65 (14% upside) price target by SunTrust Robinson.
- Catalent (NYSE:CTLT) upgraded to Outperform from Market Perform with a $26 (midpoint)(10% upside) price target by Wells Fargo. Upgraded to Buy from Neutral by Bank of America.
- Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $82 (17% upside) from $76.
- Valeant Pharmaceuticals (NYSE:VRX) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $35 (57% upside) from $50.
- AveXis (NASDAQ:AVXS) downgraded to Hold from Buy by Jefferies. Price target lowered to $39 (3% downside risk) from $42.
- Surgical Care Affiliates (NASDAQ:SCAI) downgraded to Neutral from Buy by JPMorgan. Price target maintained at $48 (3% upside).
- ACADIA Pharmaceuticals (NASDAQ:ACAD) downgraded to Neutral from Buy by Bank of America.
- Express Scripts Holdings (NASDAQ:ESRX) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target raised to $70 (9% downside risk) from $67.
- Perrigo (NYSE:PRGO) downgraded to Hold from Buy by Argus Research.
- CVS Health (NYSE:CVS) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $104 (11% upside) from $111.
Thu, May 5, 5:38 PM
- In addition to missing Q1 sales estimates (while beating on EPS), Cerner (NASDAQ:CERN) is guiding for Q2 revenue of $1.175B-$1.25B and EPS of $0.56-$0.58, below a consensus of $1.24B and $0.58 at the midpoints. Full-year revenue guidance of $4.9B-$5.1B and EPS guidance of $2.30-$2.40 (compares with a consensus of $4.98B and $2.35) is affirmed.
- While revenue rose 14% Y/Y in Q1 to $1.14B, bookings were roughly flat at $1.17B. Cerner notes bookings grew 18% when excluding long-term bookings, which were at a record high a year ago. Q2 bookings guidance is at $1.35B-$1.48B.
- System sales, support/maintenance/service revenue, and reimbursed travel revenue all grew Y/Y. Operating expenses rose 13% to $747.1M. Free cash flow more than doubled Y/Y to $152.4M. Cerner ended Q1 with $503M in cash and $554M in debt.
- CERN -5.3% after hours to $52.50.
- Cerner's Q1 results, earnings release
Thu, May 5, 4:06 PM
Wed, May 4, 5:35 PM
- ABCO, ABTL, ACAD, ACET, AHS, AHT, AIRM, AL, ALEX, AMBR, AMH, ANET, APLE, ASYS, ATHX, ATVI, ATW, BBG, BCEI, BIO, BIOS, BLDR, BOJA, CAA, CARA, CERN, CINR, CLNE, CLVS, CMLS, CPA, CTRL, CYBR, CZR, DATA, DCT, DEPO, DIOD, DK, DKL, DV, DWA, EBS, ECOM, ED, EFC, EGAN, EGL, EGN, EGY, ELON, ENDP, ENV, EOG, ERII, ESL, EVC, EVDY, EVHC, FCE.A, FEYE, FISV, FLR, FPRX, FTD, GBDC, GEOS, GERN, GPRO, GSAT, GST, GUID, GXP, HLF, HTGC, ICPT, IMMR, IMPV, INAP, JCOM, LADR, LOCO, MAIN, MCHX, MDR, MDRX, MDVN, MELI, MHK, MITT, MNTX, MRIN, MSI, MTD, MTZ, NBIX, NGVC, NSTG, NWSA, OLED, OMED, OUT, OVAS, PACD, PCTY, PEGA, PETX, PKI, PMT, POST, PRSS, PTCT, PTLA, QLGC, RPTP, RRMS, RWT, SAAS, SEM, SEMG, SNCR, SPPI, SPWR, SPXC, SQ, SSNC, SWIR, TCRD, TEAM, TRMR, TRUE, TRQ, TRUP, TSRO, TWOU, UBNT, UEPS, UNXL, WAGE, WAIR, WEB, WIFI, WING, XNPT, Y, YELP
Wed, Feb. 17, 9:14 AM
Tue, Feb. 16, 4:20 PM
- Though Cerner (NASDAQ:CERN) beat Q4 estimates, the company reported bookings growth slowed to 16% Y/Y (to $1.35B) from Q3's 44% (to $1.59B). Both Q3 and Q4's growth rates benefited from the purchase of Siemens' healthcare IT arm (closed in Feb. 2015); Q4 bookings growth trailed revenue growth of 27%.
- Also: Q1 new business bookings guidance is at $1.15B-$1.25B. Q1 2015 bookings totaled $1.2B.
- Sales/EPS guidance is in-line: Q1 revenue of $1.15B-$1.2B and EPS of $0.52-$0.54 vs. a consensus of $1.18B and $0.54, and 2016 revenue of $4.9B-$5.1B and EPS of $2.30-$2.40 vs. a consensus of $5.02B and $2.36.
- Cerner's backlog still rose 34% Y/Y to reach $14.2B at the end of Q4. Free cash flow rose 86% Y/Y in Q4 to $186.4M; it was down 18% over the whole of 2015 to $320.7M. Cerner ended 2015 with $513M in cash and $605M in debt/capital lease obligations.
- CERN -10.9% after hours to $49.41.
- Cerner's Q4 results, earnings release
Tue, Feb. 16, 4:03 PM
Mon, Feb. 15, 5:35 PM
Thu, Jan. 7, 11:29 AM
- A little over three months after upgrading Cerner (CERN +1.1%) to Outperform, RBC has named the healthcare IT giant a Top Pick. Peer Allscripts (MDRX +1%), meanwhile, has been upgraded to Outperform from Market Perform. Both companies remain in positive territory on a weak morning for stocks.
- Raymond James downgraded Allscripts on Monday in the wake of an autumn rally. Cerner went into trading today less than $2 above a 52-week low of $55.82; shares tumbled in November following a Q3 revenue miss and soft Q4 guidance.
Nov. 4, 2015, 9:15 AM| Nov. 4, 2015, 9:15 AM | 2 Comments
Nov. 3, 2015, 4:25 PM
- In addition to missing Q3 revenue estimates (while posting in-line EPS), Cerner (NASDAQ:CERN) is guiding for Q4 revenue of $1.15B-$1.2B and EPS of $0.56-$0.58, below a consensus of $1.24B and $0.61. New business bookings are expected to total $1.45B-$1.55B.
- Bookings (boosted by the Siemens Health acquisition) rose 44% Y/Y in Q3 to $1.59B, topping revenue of $1.13B (+34%, also lifted by the Siemens deal). Backlog rose 37% to $13.9B. System sales totaled $325.1M, support, maintenance, and services $783.8M, and reimbursed travel $18.9M.
- GAAP operating expenses rose 41% to $721.9M, and free cash flow totaled $111.4M (compares with adjusted net earnings of $188.7M). Cerner ended Q3 with $463M in cash, and $630M in long-term debt.
- Shares have fallen to $59.53 after hours. Peer Quality Systems (NASDAQ:QSII) is down 1.5% to $14.06, after rising 3.7% in regular trading.
- Cerner's Q3 results, PR
Nov. 3, 2015, 4:03 PM
- Cerner (NASDAQ:CERN): Q3 EPS of $0.54 in-line.
- Revenue of $1.13B (+34.5% Y/Y) misses by $40M.
Nov. 2, 2015, 5:35 PM
- ACHC, AFG, AIV, AMSG, ASH, ATVI, AWR, BIO, BKH, CBPO, CBS, CERN, CHEF, CHUY, CIM, CKP, CSU, CSV, CVC, DAC, DENN, DHT, DK, DKL, DVA, DVN, ECYT, ENPH, ENSG, EPIQ, ETSY, EVRI, FANG, FARO, FIVN, FLTX, FMI, FOGO, GHDX, GMED, GRPN, HCI, HL, HLF, HRZN, IAG, IPHS, IRWD, ITRI, IVR, JCOM, KEG, LLNW, MPO, MTZ, MXL, MYGN, NFX, NYMT, OAS, OCLR, OESX, OFIX, OKE, OKS, ORA, PAA, PAGP, PAYC, PBPB, PKD, QUAD, REGI, RIGL, RLOC, RP, RPAI, RXN, SLW, SSNI, SUPN, TDW, TMH, TSLA, TSRA, TX, UNTD, USNA, VNDA, WBMD, WR, WTR, X, XEC, XOXO, XXIA, Y, ZAGG, ZEN, ZNGA
Oct. 2, 2015, 8:09 AM
- Concordia Healthcare (NASDAQ:CXRX) initiated with Outperform rating and $86 (90% upside) price target by RBC.
- Mednax (NYSE:MD) initiated with Buy rating and $88 (15% upside) price target by Mizuho Securities.
- Valeant Pharmaceuticals (NYSE:VRX) initiated with Buy rating and $290 (61% upside) price target by B of A Merrill Lynch. Downgraded to Equal Weight from Overweight by Morgan Stanley with price target of $200 (11% upside) down from $284.
- Endo International (NASDAQ:ENDP) initiated with Buy rating and price target of $88 (26% upside) by Deutsche Bank.
- Celgene (NASDAQ:CELG) upgraded to Overweight from Neutral with $152 (35% upside) price target by JP Morgan.
- Cerner (NASDAQ:CERN) upgraded to Outperform from Sector Perform by RBC. Price target raised to $70 (17% upside) from $68.
- Bristol-Myers Squibb (NYSE:BMY) upgraded to Buy from Neutral by UBS. Price target raised to $75 (25% upside) from $65.
- Johnson & Johnson (NYSE:JNJ) upgraded to Buy from Hold by Deutsche Bank. Price target maintained at $110 (18% upside).
- Vertex Pharmaceuticals (NASDAQ:VRTX) upgraded to Buy from Hold by Argus Research. Price target maintained at $126 (18% upside).
- Ilumina (NASDAQ:ILMN) downgraded to Market Perform from Outperform by Leerink. Price target lowered to $185 (18% upside) from $225.
- Fibrocell Science (NASDAQ:FCSC) downgraded to Neutral from Outperform by Wedbush. Price target lowered to $6 (61% upside) from $7.
Sep. 29, 2015, 10:16 AM
- RBC has upgraded Cerner (NASDAQ:CERN) to Outperform, and hiked its target by $2 to $70.
- The healthcare IT giant is down 7% YTD. Shares go for 24x a 2016 EPS consensus of $2.52. A $245M buyback was launched earlier this month.
- Update: More details here. RBC's David Francis argues Cerner's recent selloff presents a "unique opportunity to own a market leader," and states checks point to an acceleration in RFP activity for what used to be Siemens' healthcare IT unit.
Sep. 21, 2015, 6:52 PM
- Wynn Resorts (NASDAQ:WYNN), Viacom (NASDAQ:VIAB) and Dollar Tree (NASDAQ:DLTR) headline Goldman Sachs' list of 25 companies that could post outsized returns even as more and more stocks are moving in lock-step.
- Goldman’s picks come as return dispersion - the performance gap among stocks - has sunk lately amid turmoil in China and concerns about when the Fed will raise interest rates that has pushed stock correlations to their highest level since 2011.
- Given the low-dispersion setting, Goldman says investors should focus on these 25 stocks that have high “dispersion scores” and 15%-plus upside to the firm’s targets: WYNN, VIAB, DLTR, UAL, LUV, URBN, CBG, JNPR, MPC, NFLX, HBI, SIG, CRM, CERN, VLO, KMX, ENDP, CTSH, ISRG, ETFC, TSN, CCE, CI, REGN, GT
Cerner Corp. designs, develops, markets, installs, hosts and supports health care information technology, health care devices, hardware and content solutions for health care organizations and consumers. It also provides a wide range of value-added services, including implementation and training,... More
Industry: Healthcare Information Services
Country: United States
Other News & PR